Du Y, Dodel RC, et al.stwood BJ, Bales KR, Gao F, Lohmuller F, Muller U, et al.

Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology 2000;55(4):480-483

Dunn SL, Young et al., Hall MD, McNulty S.

Activation of astrocyte intracellular signaling pathways by interleukin-1 in rat primary striatal cultures. Glia 2002;37(1):31-42

Durany N, Michel T, Kurt J, Cruz-Sanchez FF, Cervas-Navarro J, Riederer P.

Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. Int J Dev Neurosci 2000;18(8):807-813

Dyer RB, McMurray CT.

Mutant protein in Huntington disease is resistant to proteolysis in affected brain. Nat Genet 2001;29(3):270-278

Edvinsson L, Minthon L, Ekman R, Gustafson L.

Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration. Dementia 1993; 4(3-4):167-171

Engelborghs S, De Deyn PP.

Biological and genetic markers of sporadic Alzheimer's disease. Acta Med Okayama 2001;55(2):55-63

Evert BO, Wullner U, Klockgether T.Cell death in polyglutamine diseases. Cell Tissue Res 2000;301(1):189-204

Evin G, Smith MJ, Tziotis A, McLean C et al.

Alternative transcripts of presenilin-1 associated with frontotemporal dementia. Neuroreport 2002;13(6):917-921

Fahnestock M, Michalski B, Xu B, Coughlin MD.

The precursor pro-nerve growth factor is the predominant form of nerve growthfactor in brain and is increased in Alzheimer's disease.

Mol Cell Neurosci 2001;18(2):210-220

Farrer LA, Sherbatich T, Keryanov SA, Korovaitseva GI, Rogaeva et al, et al.

Association between angiotensin-converting enzyme and Alzheimer disease. Arch Neurol 2000;57(2):210-214

Fassbender K, Fatar M, Ragoschke A, Picard M, Bertsch T, Kuehl S, Hennerici M.

Subacute but not acute generation of nitric oxide in focal cerebral ischemia. Stroke 2000;31(9):2208-2211

Fernandez-Novoa L, Cacabelos R.Histamine function in brain disorders. Behav Brain Res 2001;124(2):213-233

Ferrarese C, Aliprandi A, Tremolizzo L, Stanzani L, De Micheli A, et al.

Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology 2001;57(4):671-675

Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, Rey MJ, et al.

Phosphorylated map kinase (ERK1, ERK2) expression is associated with et al.rly tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.

Brain Pathol 2001;11:144-158

Ferrer I, Puig B, Krupinsk J, Carmona M, Blanco R.Fas and Fas ligand expression in Alzheimer's disease. Acta Neuropat 2001;102(2):121-131

Fiebich BL, Schleicher S, Spleiss O, Czygan M, Hull M.

Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C.

J Neurochem 2001;79(5):950-958

Fox C.

Neuroprotective effects of GDNF against 6-OHDA in young and aged rats. Brain Res 2001;896(1-2):56-63.

Foy CJ, Ardill J, Filmore D, Lawson JT, Passmore AP.

Plasma somatostatin and gastrointestinal peptides in Alzheimer's disease and vascular dementia. QJM 2001;94(11):631-635

Frenkel D, et al.

Immunization against Alzheimer’s beta-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci U S A 2000; 97:11455-11459

Friedland RP, Shi J, Lamanna JC, Smith MA, Perry G.

Prospects for noninvasive imaging of brain amyloid beta in Alzheimer's disease. Ann N Y Acad Sci 2000;903:123-128

Fukamachi S, Furuta A, Ikeda T, Ikenoue T, Kaneoka T, Rothstein JD, Iwaki T.

Altered expressions of glutamate transporter subtypes in rat model of neonatal cerebral hypoxia- ischemia.

Brain Res Dev Brain Res 2001;132(2):131-139

Furukawa N, Arai N, Goshima Y, Miyamae T, Ohshima E, Suzuki F.еа.

Endogenously released DOPA is a causal factor for glutamate release and resultant delayed neuronal cell death by transient ischemia in rat striata.

J Neurochem 2001;76(3):815-824

Gill R, Soriano M, Blomgren K, Hagberg H, Wybrecht R, Miss MT, Hoefer S, et al.

Role of caspase-3 activation in cerebral ischemia-induced neurodegeneration in adult and neonatal brain.

J Cereb Blood Flow Metab 2002;22(4):420-430

Gomez JM, Aguilar M, Soler J.

Growth hormone and thyrotropin hormone secretion in Alzheimer's disease. J Nutr Health Aging 2000;4(4):229-232

Grammas P, Ovase R.

Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol Aging 2001;22(6):837-842

Grasso G.

Neuroprotective effect of recombinant human erythropoietin in experimental subarachnoid hemorrhage.

J Neurosurg Sci 2001;45(1):7-14

Grau AJ, Reis A, Buggle F, Al-Khalaf A, Werle E, Valois N, Bertram M, et al.

Monocyte function and plasma levels of interleukin-8 in acute ischemic stroke. J Neurol Sci 2001;192(1-2):41-47

Green AR, Hainsworth AH, Jackson DM.

GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology 2000;39(9):1483-1494

Gueguen Y, Bertrand P, Ferrari L, Batt AM, Siest G.

Control of apolipoprotein E secretion by 25-hydroxycholesterol and proinflammatory cytokines in the human astrocytoma cell line CCF-STTG1.

Cell Biol Toxicol 2001;17(3):191-199

Gulesserian T, Engidawork E, Cairns N, Lubec G.

Increased protein levels of serotonin transporter in frontal cortex of patients with Down syndrome. Neurosci Lett 2000;296(1):53-57

Guyot LL, Diaz FG, O'Regan MH, Song D, Phillis JW.

The effect of topical insulin on the release of excitotoxic and other amino acids from the rat cerebral cortex during streptozotocin-induced hyperglycemic ischemia.

Brain Res 2000;872(1-2):29-36

Haas J, Storch-Hagenlocher B, Biessmann A, Wildemann B.

Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with beta-amyloid 1-42 in vitro.

Neurosci Lett 2002;322(2):121-125

Hackam AS, Yassa AS, Singaraja R, Metzler M, Gutekunst CA, Gan L, et al.

Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain.

J Biol Chem 2000;275(52):41299-41308

Halterman MW, Miller CC, Federoff HJ.

Hypoxia-inducible factor-1alpha mediates hypoxia-induced delayed neuronal death that involves p53. J Neurosci 1999;19(16):6818-6824

Harrigan MR, Ennis SR, Masada T, Keep RF.

Intraventricular infusion of vascular endothelial growth factor promotes cerebral angiogenesis with minimal brain edema.

Neurosurgery 2002;50(3):589-598

Hartlage-Rubsamen M, Apelt J, Schliebs R.

Fibrillary beta-amyloid deposits are closely associated with atrophic nitric oxide synthase (NOS)- expressing neurons but do not upregulate the inducible NOS in transgenic Tg2576 mouse brain with Alzheimer pathology.

Neurosci Lett 2001;302(2-3):73-76

Harukuni I, Hurn PD, Crain BJ.

Deleterious effect of beta-estradiol in a rat model of transient forebrain ischemia. Brain Res 2001;900(1):137-142

Hayamizu TF, Chan PT, Johanson CE.

FGF-2 immunoreactivity in adult rat ependyma and choroid plexus: responses to global forebrain ischemia and icv FGF-2.

Neurol Res 2001;23(4): 353-358

He Z, He YJ, Day AL, Simpkins JW.

Proestrus levels of estradiol during transient global cerebral ischemia improves the histological outcome of the hippocampal CA1 region: perfusion-dependent and- independent mechanisms. J Neurol Sci 2002;193(2):79-87

Heckmann JG, Erbguth FJ, Hilz MJ, Lang CJ, Neundorfer B.

[Cerebrovascular circulation from a clinical view. Historical review, physiology, pathophysiology, and therapeutic aspects]

Med Klin 2001;96(10):583-592

Heininger K.

A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events. Rev Neurosci 2000;11 Spec No:213-328

Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schugardt N, et al.

Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy.

PNAS USA 2000;97(12):6739-6744

Herdegen T, Leah JD.

Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins.

Brain Res Brain Res Rev 1998;28(3):370-490

Hock C, Heese K, Hulette C, Rosenberg C, Otten U.

Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 2000;57(6):846-851

Hock C, Heese K, Muller-Spahn F, Huber P, Riesen W, Nitsch RM, Otten U.Increased CSF levels of nerve growth factor in patients with Alzheimer's disease. Neurology 2000;54(10):2009-2011

Hock CH, Heese K, Olivieri G, Hulette CH, Rosenberg C, Nitsch RM, Otten U.

Alterations in neurotrophins and neurotrophin receptors in Alzheimer's disease. J Neural Transm Suppl 2000;59:171-174

Не нашли, что искали? Воспользуйтесь поиском по сайту: